
The study aimed to evaluate the safety profile of the mRNA-1273 vaccine across cancer patients and its relationship to patients' demographics. Local ADRs were reported more frequently after the first and second dose than after the third (41.9%, 43% and 31.1% of the patients, respectively), while systemic ADRs followed the opposite pattern (16.1%, 34.4% and 52.6% of the patients, respectively). Women had 5.79 times higher odds of exhibiting systemic ADRs after the third dose than males. Increasing age was associated with a decreased likelihood of exhibiting ADRs. The mRNA-1273 vaccine shows a tolerable safety profile. The likelihood of ADRs appears to be associated with gender and age. Its association with ECOG scores needs to be more evident. Further studies are required to elucidate this data in cancer patients.
Like
Save
Share